Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients
- PMID: 596366
- DOI: 10.1002/ajh.2830020303
Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients
Abstract
A critical factor limiting the availability of histocompatible platelet transfusions for alloimmunized, thrombocytopenic patients is the large pool of HLA-typed donors needed to procure platelets perfectly matched for HLA antigens. We have, therefore, investigated the effectiveness of platelets obtained from donors having lesser degrees of histocompatibility. In 421 transfusions administered to 59 alloimmunized patients who were refractory to "random donor" platelets, it was found that platelets mismatched for 1 or 2 "cross-reactive" HLA antigens were in most instances as effective in increasing circulating platelet levels as perfectly matched platelets. A significant number of patients also responded to platelets from donors selectively mismatched for non-cross-reactive HLA antigens. The latter group had a significantly reduced frequency of the antigen HLA-A2 (13%) in comparison to the total patient population (49%). Use of donors whose HLA antigens are serologically cross-reactive with those of alloimmunized patients provides approximately 10 times as many prospective donors as does selection based on matching for HLA and simplifies the procurement of hemostatically effective platelets for such patients.
Similar articles
-
Influence of HLA-A2 on the effectiveness of platelet transfusions in alloimmunized thrombocytopenic patients.Blood. 1977 Sep;50(3):407-12. Blood. 1977. PMID: 884318
-
A cost-effectiveness evaluation of platelet crossmatching and HLA matching in the management of alloimmunized thrombocytopenic patients.Transfusion. 1989 Mar-Apr;29(3):201-7. doi: 10.1046/j.1537-2995.1989.29389162723.x. Transfusion. 1989. PMID: 2493693
-
Platelet crossmatching. A direct approach to the selection of platelet transfusions for the alloimmunized thrombocytopenic patient.Am J Clin Pathol. 1988 Jul;90(1):69-72. doi: 10.1093/ajcp/90.1.69. Am J Clin Pathol. 1988. PMID: 3389345
-
Donor selection in platelet transfusion therapy of alloimmunized thrombocytopenic patients.Prog Clin Biol Res. 1978;28:229-43. Prog Clin Biol Res. 1978. PMID: 88057 Review. No abstract available.
-
Use of HLA- and HPA--matched platelets in alloimmunized patients.Vox Sang. 1998;74 Suppl 2:359-63. doi: 10.1111/j.1423-0410.1998.tb05443.x. Vox Sang. 1998. PMID: 9704468 Review.
Cited by
-
HLAMatchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients.Blood. 2006 Feb 15;107(4):1680-7. doi: 10.1182/blood-2004-10-4080. Epub 2005 Nov 3. Blood. 2006. PMID: 16269623 Free PMC article.
-
The Johns Hopkins Oncology Clinical Information System.J Med Syst. 1983 Apr;7(2):147-74. doi: 10.1007/BF00995121. J Med Syst. 1983. PMID: 6875417
-
[Serologic properties of antigens HLA-A, B and C].Can Med Assoc J. 1981 Mar 15;124(6):690-7. Can Med Assoc J. 1981. PMID: 7008927 Free PMC article. Review.
-
Anti-HLA antibody formation increases the chances of platelet refractoriness in platelet-transfused patients: a systematic review with meta-analysis.Hematol Transfus Cell Ther. 2025 Apr-Jun;47(2):103821. doi: 10.1016/j.htct.2025.103821. Epub 2025 Apr 16. Hematol Transfus Cell Ther. 2025. PMID: 40245603 Free PMC article. Review.
-
Platelet transfusions.Can Med Assoc J. 1979 Nov 17;121(10):1353-8. Can Med Assoc J. 1979. PMID: 391376 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials